Page 31 - EVALUATION OF TREATMENT FOR HEAVY MENSTRUAL BLEEDING by Herman, Malou

Pictorial Blood Assessment Chart and endometrial ablation outcome
meaning of PBAC as an outcome tool. We found that a PBAC score of 59 points or a decrease of around 90% in score gives the highest sensitivity and specificity for satisfaction and no re-intervention for these treated women. This result is not comparable to the “normal period”, indicated as <130point by Hald. These treated women seem to search for a lower amount of blood loss. We believe PBAC could now be a meaningful outcome measure and we should use the information of this study in future HMB studies. We propose to use the PBAC as primary endpoint in studies on HMB and to use it in clinical practice as a measure to assess the effectiveness of treatment. Of course, future studies must first validate the PBAC score after treatment.
Acknowledgements
We thank the University of Birmingham Clinical Trial Unit for developing and sharing the IPDMA dataset with us. We thank all the authors of identified trials who sent data through the previous related review8. The following authors provided us with individual patient data from their trials for this paper:
• J. Abbott, University of New South Wales, Sydney, Australia
• M.Y. Bongers, Maxima Medical Centre, Veldhoven, Netherlands;
• J-L Brun, Hopital Universitaire Pellegrin, Bordeaux, France;
• Busfield, National Women’s Hospital, University of Auckland,
Auckland, New Zealand
• J. Cooper (2004trial), data supplied by Microsulis Medical, Hampshire,
UK;
• J.Hawe, Countess of Chester Hospital ,Chester, UK;
• W.R. Meyer, data supplied by Ethicon, NJ, US
• J.P.M. Penninx, Maxima Medical Centre, Veldhoven, Netherlands
7
93